Profiles

Gheorghe Doros, PhD

Professor, Biostatistics - Boston University School of Public Health

617-358-2494
doros@bu.edu
Crosstown Center - 331
View Full Profile at BUMC

Biography

Gheorghe Doros is Professor of Biostatistics and director of the Biostatistics Consulting Group. He received his PhD in Statistics from Yale University and joined BUSPH’s Department of Biostatistics in 2006 after spending two years at Eli Lilly, as a member of that company's Drug Discovery and Toxicology department. Dr. Doros’s research on methodological approaches and strategies has been concentrated in the area of clinical trials, more specifically on Bayesian approaches to clinical trials and the area of placebo response in clinical trials. The outcome of his work has been a corner stone in developing a host of collaborations with outstanding faculty, clinicians, and researchers at the Boston University Medical Campus and at other institutions. These productive collaborations have resulted in several federally funded grants. Dr. Doros authored and co-authored many peer-reviewed publications of original and innovative research which has had a major impact on the field. On the majority of publications, Dr. Doros is the lead statistician author. He demonstrated continuing record of multidisciplinary research that has had a major impact on the rapidly changing field. His publications on clinical trials; most proposing the design, analysis and new methodologies or of significant contributions to this field.

Dr. Doros is a very active and effective teacher and mentor in the department of Biostatistics. His teaching philosophy is to pursue an active approach to learning and to engage students to think critically. He taught core and elective courses for Master and PhD-level courses. The excellent course evaluations he received attests to his ability in engaging students in active learning. Dr. Doros has been awarded the excellence in teaching three times in three years.

On a national level, Dr. Doros has served as an Associate Editor for the BioMed Central’s journal Trials and as a reviewer for a number of academic journals. He served as a member of the merit review subcommittee for Epidemiology of the Department of Veteran Affairs and a member NHLBI-Ancillary Studies in Clinical Trials between 2012 and 2014. He has served as a statistical expert on a number of Independent Data Monitoring Committee(IDMC) for clinical trials and clinical programs. He served or seves as a senior consultant on multicenter trials and/or programs for the following organizations Pfizer, Takeda, Avanir, Sarepta and Children's Hospital.

Other Positions

  • Member, BU-BMC Cancer Center - Boston University

Education

  • Yale University, PhD Field of Study: Statistics
  • Yale University, MA Field of Study: Statistics
  • University of Bucharest, MS Field of Study: Statistics
  • University of Bucharest, BS Field of Study: Mathematics

Websites

Classes Taught

  • SPHBS849
  • SPHBS853
  • SPHBS854
  • SPHBS980

Publications

  • Published on 2/16/2026

    Conte MS, Farber A, Liu IH, Chang RW, Doros G, Herman CR, Hiramoto JS, McGinigle KL, Siracuse JJ, Strong M, Menard MT. Open versus Endovascular Revascularisation for Femoropopliteal Disease in Patients with Chronic Limb Threatening Ischaemia. Eur J Vasc Endovasc Surg. 2026 Feb 16. PMID: 41708051.

     Read At: PubMed
  • Published on 2/2/2026

    Brooke BS, Doros G, Venermo M, Siracuse JJ, Abou-Zamzam AM, Dosluoglu HH, Motaganahalli RL, Menard MT, Farber A, Conte MS. Early Improvement in Wound, Ischaemia, and foot Infection (WIfI) Ischaemia Grade Lowers Risk of Major Amputation following Revascularisation for Chronic Limb Threatening Ischaemia. Eur J Vasc Endovasc Surg. 2026 Feb 02. PMID: 41638549.

     Read At: PubMed
  • Published on 1/12/2026

    Hicks CW, Farber A, Doros G, Kinlay S, Powell RJ, Strong MB, Rosenfield K, Aridi H, Motaganahalli R, Barleben A, Siracuse JJ, Azene E, Malas M, Conte MS, Zayed M, Menard MT. Atherectomy Is Not Associated With Improved Limb-Based Outcomes Among Patients in the BEST-CLI Trial Undergoing Endovascular Revascularization. JACC Cardiovasc Interv. 2026 Jan 12; 19(1):96-107. PMID: 41534992.

     Read At: PubMed
  • Published on 12/29/2025

    Burke NJ, Mendelson LM, Joshi T, Libbey C, Burks EJ, Prokaeva T, Spencer B, Zheng L, Doros G, Sanchorawala V, Staron A. Detection yield of surrogate tissue biopsies across amyloidosis classes: a large-scale analysis of 4,027 patients. Amyloid. 2025 Dec 29; 1-9. PMID: 41460224.

     Read At: PubMed
  • Published on 11/27/2025

    Hussain MA, Khan AA, Menard MT, Conte MS, Vouyouka AG, Doros G, Strong MB, Kalish JA, Chew D, Gasper WJ, Tan TW, Darling RC, LaMuraglia G, Rosenfield K, Farber A, Schanzer A. Contemporary outcomes of lower extremity vein bypass for chronic limb-threatening ischemia based on a post hoc comparison of the BEST-CLI and PREVENT III multicenter prospective randomized controlled trials. J Vasc Surg. 2026 Apr; 83(4):1171-1180. PMID: 41317973.

     Read At: PubMed
  • Published on 11/14/2025

    Tan TW, Dansey KD, Farber A, Doros G, Menard MT, Rosenfield K, Conte MS, Venermo M, Kolh P, Strong MB, Singh N. High rates of nonindex limb amputation in the Best Endovascular versus Best Surgical Therapy in Patients with Critical Limb Ischemia (BEST-CLI) trial. J Vasc Surg. 2026 Mar; 83(3):905-913. PMID: 41242623.

     Read At: PubMed
  • Published on 11/11/2025

    Alabi O, Doros G, Hamouda M, Conte MS, Farber A, Kirksey L, Menard MT, Kernodle A, McGinigle K, Moreira C, Rosenfield K, Strong MB, Ulloa JG, Kaufman JA, Malas M, Rowe VL. Examination of Race and Ethnicity After Revascularization in the BEST-CLI Trial. Ann Surg. 2025 Nov 11. PMID: 41214473.

     Read At: PubMed
  • Published on 11/6/2025

    Powell RJ, Menard MT, Rosenfield K, Strong MB, Conte MS, Doros G, Ezra A, Garg N, Mena-Hurtado C, Lane JS, Shah SK, Venermo M, Zhou W, Farber A. Influence of specialty on endovascular practice patterns and outcomes in the BEST-CLI Trial. J Vasc Surg. 2026 Apr; 83(4):1160-1170. PMID: 41205838.

     Read At: PubMed
  • Published on 11/1/2025

    Song Y, Fava M, Kim C, Yeh RW, Doros G. Estimating Causal Treatment Effects in the Sequential Parallel Comparison Design (SPCD). Stat Med. 2025 Nov; 44(25-27):e70319. PMID: 41249861.

     Read At: PubMed
  • Published on 9/2/2025

    Avila Rodriguez AM, Hu X, Varga C, Comenzo R, Sarosiek S, Sloan JM, Sanchorawala V, Doros G, Quillen K. Comparable peri-transplant mortality and incidence of febrile neutropenia after high-dose melphalan and autologous stem cell transplantation in patients with plasma cell dyscrasias treated as outpatient versus inpatient. Br J Haematol. 2025 Oct; 207(4):1679-1683. PMID: 40898649.

     Read At: PubMed

View 371 more publications:View Full Profile at BUMC

News & In the Media

View all profiles